Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aska Of Japan To Start Phase II Europe Trials For IBD Drug

This article was originally published in PharmAsia News

Executive Summary

Japan's Aska Pharmaceutical plans to begin European Phase II trials of its AKP-001 compound for treating inflammatory bowel disease in the next fiscal year. Aska also is developing the drug for treating Crohn's disease. If the drug wins regulatory approval, Aska, which has no sales force outside of Japan, plans to license development and marketing rights in Europe and the United States. It plans to develop and market the drug in Japan on its own. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts